ArticleLeukemia2014
Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia.
Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Myelodysplastic syndromes, version 2.2015.Journal of the National Comprehensive Cancer Network : JNCCN · 2015Guideline
- Application of next-generation sequencing in the treatment of myelodysplastic syndrome: from mechanisms to clinical practice.Blood science (Baltimore, Md.) · 2026Review
- Cisplatin-induced therapy-related myelodysplastic syndrome during avelumab maintenance therapy for metastatic urothelial carcinoma.International cancer conference journal · 2025Article
- Impact of primary cancer history and molecular landscape in therapy-related myeloid neoplasms.Frontiers in oncology · 2025Article
- Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective.Leukemia · 2023Article
- Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes.International journal of molecular sciences · 2022Review
- De Novo and Therapy-Related Myelodysplastic Syndromes: Analogies and Differences.Mediterranean journal of hematology and infectious diseases · 2022Review
- Article
- Second malignancies in multiple myeloma; emerging patterns and future directions.Best practice & research. Clinical haematology · 2020Review
- Article
- [Myelodysplastic syndromes: recent advances in prognostic risk stratification systems].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?Leukemia · 2017Article
- Is there a pressing need for improving prognostication strategies in therapy-related myelodysplastic syndromes?Leukemia · 2017Article
- Myelodysplastic Syndromes: Updates and Nuances.The Medical clinics of North America · 2017Review
- Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?Hematology. American Society of Hematology. Education Program · 2016Review
- Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016Article
- Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.Oncotarget · 2016Article
- Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015Article
- TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.Journal of hematology & oncology · 2015Article
- High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
23787392What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.